Literature DB >> 22224173

Current state of surgical treatment of liver metastases from colorectal cancer.

Reinhart T Grundmann1.   

Abstract

Hepatic resection is the procedure of choice for curative treatment of colorectal liver metastases (CLM). Objectives of surgical strategy are low intraoperative blood loss, short liver ischemic times and minor postoperative morbidity and mortality. Blood loss is an independent predictor of mortality and compromises, in common with postoperative complications, long-term outcome after hepatectomy for CLM. The type of liver resection has no impact on the outcome of patients with CLM; wedge resections are not inferior to anatomical resections in terms of tumor clearance, pattern of recurrence or survival. Despite the lack of proof of survival benefit, routine lymphadenectomy has been advocated, allowing the detection of microscopic lymph node metastases and with prognostic value. In experienced hands, minimally invasive liver surgery is safe with acceptable morbidity and mortality and oncological results comparable to open hepatic surgery, but with reduced blood loss and earlier recovery. The European Colorectal Metastases Treatment Group recommended treating up front with chemotherapy for patients with both resectable and unresectable CLM. However, neoadjuvant chemotherapy can induce damage to the remnant liver, dependent on the number of chemotherapy cycles. Therefore, in our opinion, preoperative chemotherapy should be reserved for patients whose CLM are marginally resectable or unresectable. A meta analysis of randomized trials dealing with perioperative chemotherapy for the treatment of resectable CLM demonstrated a benefit of systemic chemotherapy but did not answer the question of whether a neoadjuvant or adjuvant approach should be preferred. Analysis of the literature demonstrates that the results of specialized centers cannot be attained in the reality of comprehensive patient care. Reasons behind the commonly poorer results seen in cancer networks as compared with literature-based data are, on the one hand, geographical disparities in access to specialized surgical and medical care. On the other hand, a selection bias in the reports of the literature may be assumed. Studies of surgical resection for CLM derive almost exclusively from case series generally drawn from large academic centers where patient selection or surgical expertise is superior to what is found in many communities. Therefore, we may conclude that the comprehensive propagation of the standards outlined in this paper constitutes a major task in the near future to reduce the variations in survival of patients with CLM.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Liver metastases; Outcome; Surgery

Year:  2011        PMID: 22224173      PMCID: PMC3251742          DOI: 10.4240/wjgs.v3.i12.183

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  150 in total

1.  Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study.

Authors:  Daniel Jaeck; Hiroshi Nakano; Philippe Bachellier; Keiichiro Inoue; Jean-Christophe Weber; Elie Oussoultzoglou; Philippe Wolf; Marie-Pierre Chenard-Neu
Journal:  Ann Surg Oncol       Date:  2002-06       Impact factor: 5.344

2.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

Review 3.  Controversies in the use of portal vein embolization.

Authors:  Thomas M van Gulik; Jacomina W van den Esschert; Wilmar de Graaf; Krijn P van Lienden; Olivier R C Busch; Michal Heger; Otto M van Delden; Johan S Laméris; Dirk J Gouma
Journal:  Dig Surg       Date:  2009-02-12       Impact factor: 2.588

Review 4.  Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.

Authors:  D Zorzi; A Laurent; T M Pawlik; G Y Lauwers; J-N Vauthey; E K Abdalla
Journal:  Br J Surg       Date:  2007-03       Impact factor: 6.939

5.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

6.  Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?

Authors:  René Adam; Robbert J de Haas; Dennis A Wicherts; Thomas A Aloia; Valérie Delvart; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases.

Authors:  D A Wicherts; R J de Haas; P Andreani; D Sotirov; C Salloum; D Castaing; R Adam; D Azoulay
Journal:  Br J Surg       Date:  2010-02       Impact factor: 6.939

8.  Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database.

Authors:  Justin B Dimick; John A Cowan; James A Knol; Gilbert R Upchurch
Journal:  Arch Surg       Date:  2003-02

Review 9.  Operative mortality after hepatic resection: are literature-based rates broadly applicable?

Authors:  Bolanle Asiyanbola; David Chang; Ana Luiza Gleisner; Hari Nathan; Michael A Choti; Richard D Schulick; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-02-12       Impact factor: 3.452

10.  Evidence for a synchronous operative approach in the treatment of colorectal cancer with hepatic metastases: a case matched study.

Authors:  S J Moug; D Smith; E Leen; C Roxburgh; P G Horgan
Journal:  Eur J Surg Oncol       Date:  2010-01-19       Impact factor: 4.424

View more
  12 in total

Review 1.  Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?

Authors:  Peter Ihnát; Petr Vávra; Pavel Zonča
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

2.  Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries.

Authors:  Fuyan Shi; Chen Wang; Yujia Kong; Liping Yang; Juan Li; Gaopei Zhu; Jing Guo; Qingfeng Zheng; Bo Zhang; Suzhen Wang
Journal:  J Hepatocell Carcinoma       Date:  2020-10-19

Review 3.  Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when?

Authors:  Alberto Cacciola; Silvana Parisi; Consuelo Tamburella; Sara Lillo; Gianluca Ferini; Laura Molino; Giuseppe Iatì; Antonio Pontoriero; Antonio Bottari; Silvio Mazziotti; Giuseppe Cicero; Fabio Minutoli; Alfredo Blandino; Stefano Pergolizzi
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-21

4.  Surgical management of colorectal peritoneal metastases: treatment and outcomes compared with hepatic metastases.

Authors:  Grace Hwei Ching Tan; Melissa Ching Ching Teo; Wallace Chen; Ser Yee Lee; Deanna Wan Jie Ng; Chee Kian Tham; Khee Chee Soo
Journal:  J Gastrointest Cancer       Date:  2013-06

Review 5.  Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review.

Authors:  Alberto Zaniboni; Giordano Savelli; Claudio Pizzocaro; Pietro Basile; Valentina Massetti
Journal:  Gastroenterol Res Pract       Date:  2015-05-11       Impact factor: 2.260

6.  Prognostic Analysis of 102 Patients with Synchronous Colorectal Cancer and Liver Metastases Treated with Simultaneous Resection.

Authors:  Ye-Fan Zhang; Rui Mao; Xiao Chen; Jian-Jun Zhao; Xin-Yu Bi; Zhi-Yu Li; Jian-Guo Zhou; Hong Zhao; Zhen Huang; Yong-Kun Sun; Jian-Qiang Cai
Journal:  Chin Med J (Engl)       Date:  2017-06-05       Impact factor: 2.628

Review 7.  Stereotactic body radiotherapy using the CyberKnife® system in the treatment of patients with liver metastases: state of the art.

Authors:  Peter Ihnát; Eva Skácelíková; Milan Tesař; Igor Penka
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

8.  Minimal invasive surgery in treatment of liver metastases from colorectal carcinomas: case studies and survival rates.

Authors:  Domenico Loffredo; Alberto Marvaso; Sandro Ceraso; Nicola Cinelli; Aldo Rocca; Mario Vitale; Michele Rossi; Eugenio Genovese; Bruno Amato; Mariapia Cinelli
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

9.  Lymph node ratio as a valuable prognostic factor for patients with colorectal liver-only metastasis undergoing curative resection.

Authors:  Yuxiang Deng; Jianhong Peng; Yujie Zhao; Qiaoqi Sui; Ruixia Zhao; Zhenhai Lu; Miaozhen Qiu; Junzhong Lin; Zhizhong Pan
Journal:  Cancer Manag Res       Date:  2018-07-17       Impact factor: 3.989

10.  Does the Preoperative Prognostic Nutritional Index Predict Survival in Patients with Liver Metastases from Colorectal Cancer Who Underwent Curative Resection?

Authors:  Yujie Zhao; Yuxiang Deng; Jianhong Peng; Qiaoqi Sui; Junzhong Lin; Miaozhen Qiu; Zhizhong Pan
Journal:  J Cancer       Date:  2018-05-25       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.